Literature DB >> 22693110

Brain amyloid and cognition in Lewy body diseases.

Stephen N Gomperts1, Joseph J Locascio, Marta Marquie, Andrea L Santarlasci, Dorene M Rentz, Jacqueline Maye, Keith A Johnson, John H Growdon.   

Abstract

Many patients with PD develop PD with dementia (PDD), a syndrome that overlaps clinically and pathologically with dementia with Lewy bodies (DLB); PDD and DLB differ chiefly in the relative timing of dementia and parkinsonism. Brain amyloid deposition is an early feature of DLB and may account, in part, for its early dementia. We sought to confirm this hypothesis and also to determine whether amyloid accumulation contributes to cognitive impairment and dementia in the broad range of parkinsonian diseases. Twenty-nine cognitively healthy PD, 14 PD subjects with mild cognitive impairment (PD-MCI), 18 with DLB, 12 with PDD, and 85 healthy control subjects (HCS) underwent standardized neurologic and neuropsychological examinations and Pittsburgh compound B (PiB) imaging with PET. Apolipoprotein E (ApoE) genotypes were obtained in many patients. PiB retention was expressed as the distribution volume ratio using a cerebellar tissue reference. PiB retention was significantly higher in DLB than in any of the other diagnostic groups. PiB retention did not differ across PDD, PD-MCI, PD, and HCS. Amyloid burden increased with age and with the presence of the ApoE ε4 allele in all patient groups. Only in the DLB group was amyloid deposition associated with impaired cognition. DLB subjects have higher amyloid burden than subjects with PDD, PD-MCI, PD, or HCS; amyloid deposits are linked to cognitive impairment only in DLB. Early amyloid deposits in DLB relative to PDD may account for their difference in the timing of dementia and parkinsonism.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22693110      PMCID: PMC3725259          DOI: 10.1002/mds.25048

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  59 in total

1.  Amyloid imaging of Lewy body-associated disorders.

Authors:  Erin R Foster; Meghan C Campbell; Michelle A Burack; Johanna Hartlein; Hubert P Flores; Nigel J Cairns; Tamara Hershey; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

Authors:  Peter A Kempster; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Andrew J Lees
Journal:  Brain       Date:  2010-04-05       Impact factor: 13.501

Review 3.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

4.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

Review 5.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

6.  Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy.

Authors:  Daniel O Claassen; Val J Lowe; Patrick J Peller; Ronald C Petersen; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2010-12-31       Impact factor: 4.891

7.  Memory impairment on free and cued selective reminding predicts dementia.

Authors:  E Grober; R B Lipton; C Hall; H Crystal
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

8.  Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease.

Authors:  Mario Ezquerra; Jaume Campdelacreu; Carles Gaig; Yaroslau Compta; Esteban Muñoz; Maria Jose Martí; Francesc Valldeoriola; Eduardo Tolosa
Journal:  Neurosci Lett       Date:  2008-10-10       Impact factor: 3.046

9.  In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.

Authors:  M A Burack; J Hartlein; H P Flores; L Taylor-Reinwald; J S Perlmutter; N J Cairns
Journal:  Neurology       Date:  2010-01-05       Impact factor: 9.910

10.  Amyloid-β associated cortical thinning in clinically normal elderly.

Authors:  J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

View more
  62 in total

Review 1.  Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

Authors:  Myria Petrou; Ben A Dwamena; Bradley R Foerster; Mark P MacEachern; Nicolaas I Bohnen; Martijn Ltm Müller; Roger L Albin; Kirk A Frey
Journal:  Mov Disord       Date:  2015-04-16       Impact factor: 10.338

Review 2.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

3.  PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies.

Authors:  Stephen N Gomperts; Marta Marquie; Joseph J Locascio; Stephen Bayer; Keith A Johnson; John H Growdon
Journal:  Neurodegener Dis       Date:  2015-12-08       Impact factor: 2.977

4.  Beta-amyloid deposition in chronic traumatic encephalopathy.

Authors:  Thor D Stein; Philip H Montenigro; Victor E Alvarez; Weiming Xia; John F Crary; Yorghos Tripodis; Daniel H Daneshvar; Jesse Mez; Todd Solomon; Gaoyuan Meng; Caroline A Kubilus; Kerry A Cormier; Steven Meng; Katharine Babcock; Patrick Kiernan; Lauren Murphy; Christopher J Nowinski; Brett Martin; Diane Dixon; Robert A Stern; Robert C Cantu; Neil W Kowall; Ann C McKee
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

5.  Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions.

Authors:  Geidy E Serrano; Marwan N Sabbagh; Lucia I Sue; Jose A Hidalgo; Julie A Schneider; Barry J Bedell; Vivianna M Van Deerlin; Eunran Suh; Haruhiko Akiyama; Abhinay D Joshi; Michael J Pontecorvo; Mark A Mintun; Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 6.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

7.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

8.  Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET.

Authors:  Tengfei Guo; Matthias Brendel; Timo Grimmer; Axel Rominger; Igor Yakushev
Journal:  J Nucl Med       Date:  2016-10-06       Impact factor: 10.057

9.  Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

Authors:  Inger van Steenoven; Dag Aarsland; Daniel Weintraub; Elisabet Londos; Frédéric Blanc; Wiesje M van der Flier; Charlotte E Teunissen; Brit Mollenhauer; Tormod Fladby; Milica G Kramberger; Laura Bonanni; Afina W Lemstra
Journal:  J Alzheimers Dis       Date:  2016-08-18       Impact factor: 4.472

10.  Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.

Authors:  Lidia Sarro; Matthew L Senjem; Emily S Lundt; Scott A Przybelski; Timothy G Lesnick; Jonathan Graff-Radford; Bradley F Boeve; Val J Lowe; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Brain       Date:  2016-07-24       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.